<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>FUROSEMIDE - furosemide tablet </strong><br>PD-Rx Pharmaceuticals, Inc.<br></p></div>
<h1>FUROSEMIDE TABLETS, USP 20, 40, and 80 mg</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_46eae6df-5936-4fb1-b4e7-e1159e47af15"></a><a name="section-1"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Rx only</span></p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="LINK_cf3817ba-6e59-4bb0-9e98-4c851ece6c63"></a><a name="section-2"></a><p></p>
<h1>WARNING</h1>
<p class="First"><span class="Bold">Furosemide is a potent diuretic which, if given in excessive amounts, can lead to a profound <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> with water and <span class="product-label-link" type="condition" conceptid="4077438" conceptname="Electrolyte depletion">electrolyte depletion</span>. Therefore, careful medical supervision is required and dose and dose schedule must be adjusted to the individual patient's needs (see <a href="#LINK_3d2a4ff6-bc1e-465d-9cf1-6be94b98be1c">DOSAGE AND ADMINISTRATION</a>).</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LINK_3ee49790-7f59-4d9a-bf82-31fce6f85c7d"></a><a name="section-3"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Furosemide is a diuretic which is an anthranilic acid derivative. Furosemide Tablets for oral administration contain furosemide as the active ingredient and the following inactive ingredients: corn starch NF, lactose monohydrate NF, magnesium stearate NF, pregelatinized starch NF, and talc USP. Chemically, it is 4-chloro-N-furfuryl-5-sulfamoylanthranilic acid. Furosemide is available as white-off white tablets for oral administration in dosage strengths of 20, 40 and 80 mg. Furosemide is a white to off-white odorless crystalline powder. It is practically insoluble in water, sparingly soluble in alcohol, freely soluble in dilute alkali solutions and insoluble in dilute acids.</p>
<p>The structural formula is as follows:</p>
<div class="Figure"><img alt="This is an image of the structural formula for furosemide." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ea5805d3-400b-4978-b27d-bd2b5b1cb636&amp;name=furosemide-tablets-1.jpg"></div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_1daea8ef-12b4-41c9-898f-acf06bb6b06b"></a><a name="section-4"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Investigations into the mode of action of furosemide have utilized micropuncture studies in rats, stop flow experiments in dogs and various clearance studies in both humans and experimental animals. It has been demonstrated that furosemide inhibits primarily the absorption of sodium and chloride not only in the proximal and distal tubules but also in the loop of Henle. The high degree of efficacy is largely due to the unique site of action. The action on the distal tubule is independent of any inhibitory effect on carbonic anhydrase and aldosterone.</p>
<p>Recent evidence suggests that furosemide glucuronide is the only or at least the major biotransformation product of furosemide in man. Furosemide is extensively bound to plasma proteins, mainly to albumin. Plasma concentrations ranging from 1 to 400 mcg/mL are 91 to 99% bound in healthy individuals. The unbound fraction averages 2.3 to 4.1% at therapeutic concentrations.</p>
<p>The onset of <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> following oral administration is within 1 hour. The peak effect occurs within the first or second hour. The duration of <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuretic effect</span> is 6 to 8 hours.</p>
<p>In fasted normal men, the mean bioavailability of furosemide from furosemide tablets and furosemide oral solution is 64% and 60%, respectively, of that from an intravenous injection of the drug. Although furosemide is more rapidly absorbed from the oral solution (50 minutes) than from the tablet (87 minutes), peak plasma levels and area under the plasma concentration-time curves do not differ significantly. Peak plasma concentrations increase with increasing dose but times-to-peak do not differ among doses. The terminal half-life of furosemide is approximately 2 hours.</p>
<p>Significantly more furosemide is excreted in urine following the IV injection than after the tablet or oral solution. There are no significant differences between the two oral formulations in the amount of unchanged drug excreted in urine.</p>
<div class="Section" data-sectionCode="34082-8">
<a name="LINK_67c58d83-4947-4b9c-9b9c-60bb4c2f8381"></a><a name="section-4.1"></a><p></p>
<h2>Geriatric Population</h2>
<p class="First">Furosemide binding to albumin may be reduced in elderly patients. Furosemide is predominantly excreted unchanged in the urine. The renal clearance of furosemide after intravenous administration in older healthy male subjects (60-70 years of age) is statistically significantly smaller than in younger healthy male subjects (20-35 years of age). The initial <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuretic effect</span> of furosemide in older subjects is decreased relative to younger subjects (see <span class="Bold"><a href="#LINK_3b8780d6-0914-4a2f-982e-e89a38d1d1c3">PRECAUTIONS: Geriatric Use</a></span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_85c1c8be-9474-46f1-aba8-34ded5a9c997"></a><a name="section-5"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_76cd3dbe-5b2b-4936-8c4d-780870f7b860"></a><a name="section-5.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></h2>
<p class="First">Furosemide tablets are indicated in adults and pediatric patients for the treatment of <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> associated with <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, cirrhosis of the liver, and <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, including the <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrotic syndrome</span>. Furosemide tablets are particularly useful when an agent with greater diuretic potential is desired.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_280c56aa-5e58-4d47-9640-b3175befe4e5"></a><a name="section-5.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></h2>
<p class="First">Oral furosemide tablets may be used in adults for the treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> alone or in combination with other antihypertensive agents. Hypertensive patients who cannot be adequately controlled with thiazides will probably also not be adequately controlled with furosemide alone.</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_84231fef-0311-4ee1-a5f0-aaed4297205b"></a><a name="section-6"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Furosemide tablets are contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span> and in patients with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to furosemide.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="LINK_b57bfc89-3dac-488a-b120-99272d440956"></a><a name="section-7"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">In patients with <span class="product-label-link" type="condition" conceptid="4064161" conceptname="Cirrhosis of liver">hepatic cirrhosis</span> and <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">ascites</span>, furosemide therapy is best initiated in the hospital. In <span class="product-label-link" type="condition" conceptid="377604" conceptname="Hepatic coma">hepatic coma</span> and in states of <span class="product-label-link" type="condition" conceptid="4077438" conceptname="Electrolyte depletion">electrolyte depletion</span>, therapy should not be instituted until the basic condition is improved. Sudden alterations of fluid and electrolyte balance in patients with cirrhosis may precipitate <span class="product-label-link" type="condition" conceptid="377604" conceptname="Hepatic coma">hepatic coma</span>; therefore, strict observation is necessary during the period of <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>. Supplemental potassium chloride and, if required, an aldosterone antagonist are helpful in preventing <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> and <span class="product-label-link" type="condition" conceptid="4030381" conceptname="Metabolic alkalosis">metabolic alkalosis</span>.</p>
<p>If increasing <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span> and <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span> occur during treatment of severe progressive <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, furosemide should be discontinued.</p>
<p>Cases of <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span> and reversible or irreversible hearing impairment and <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">deafness</span> have been reported. Reports usually indicate that furosemide <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">ototoxicity</span> is associated with rapid injection, severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, the use of higher than recommended doses, <span class="product-label-link" type="condition" conceptid="4228222" conceptname="Hypoproteinemia">hypoproteinemia</span> or concomitant therapy with aminoglycoside antibiotics, ethacrynic acid, or other ototoxic drugs. If the physician elects to use high dose parenteral therapy, controlled intravenous infusion is advisable (for adults, an infusion rate not exceeding 4 mg furosemide per minute has been used) (see <span class="Bold"><a href="#LINK_1f918ac3-11da-49e4-8acd-e289712b74dc">PRECAUTIONS: Drug Interactions</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="LINK_403c84cf-6980-406e-bc23-8b2347bb7289"></a><a name="section-8"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="LINK_96f3df82-3837-4f74-bf02-d4e46a0c9b95"></a><a name="section-8.1"></a><p></p>
<h2>General</h2>
<p class="First">Excessive <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> may cause <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> and blood volume reduction with <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">circulatory collapse</span> and possibly vascular <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> and <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolism</span>, particularly in elderly patients. As with any effective diuretic, <span class="product-label-link" type="condition" conceptid="4077438" conceptname="Electrolyte depletion">electrolyte depletion</span> may occur during furosemide therapy, especially in patients receiving higher doses and a restricted salt intake. <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> may develop with furosemide, especially with brisk <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>, inadequate oral electrolyte intake, when cirrhosis is present, or during concomitant use of corticosteroids, ACTH, licorice in large amounts, or prolonged use of laxatives. Digitalis therapy may exaggerate metabolic effects of <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, especially myocardial effects.</p>
<p>All patients receiving furosemide therapy should be observed for these signs or symptoms of fluid or <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span> (<span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, <span class="product-label-link" type="condition" conceptid="4289304" conceptname="Hypochloremic alkalosis">hypochloremic alkalosis</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span> or <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>): dryness of mouth, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pains</span> or <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps</span>, muscular <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>, or <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disturbances</span> such as <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. Increases in blood glucose and alterations in glucose tolerance tests (with abnormalities of the fasting and 2-hour postprandial sugar) have been observed, and rarely, precipitation of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus has been reported.</p>
<p>In patients with severe symptoms of <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span> (because of bladder emptying disorders, <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hyperplasia</span>, urethral narrowing), the administration of furosemide can cause acute <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span> related to increased production and <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">retention of urine</span>. Thus, these patients require careful monitoring, especially during the initial stages of treatment.</p>
<p>In patients at high risk for <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">radiocontrast nephropathy</span> furosemide can lead to a higher incidence of deterioration in renal function after receiving radiocontrast compared to high-risk patients who received only intravenous hydration prior to receiving radiocontrast.</p>
<p>In patients with <span class="product-label-link" type="condition" conceptid="4228222" conceptname="Hypoproteinemia">hypoproteinemia</span> (e.g., associated with <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrotic syndrome</span>) the effect of furosemide may be weakened and its <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">ototoxicity</span> potentiated.</p>
<p>Asymptomatic <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span> can occur and <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span> may rarely be precipitated.</p>
<p>Patients allergic to sulfonamides may also be allergic to furosemide. The possibility exists of exacerbation or activation of <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span>.</p>
<p>As with many other drugs, patients should be observed regularly for the possible occurrence of <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood dyscrasias</span>, liver or kidney damage, or other idiosyncratic reactions.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="LINK_f45949a8-14d2-48c4-813f-54e33e40b7f1"></a><a name="section-8.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Patients receiving furosemide should be advised that they may experience symptoms from excessive fluid and/or electrolyte losses. The <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span> that sometimes occurs can usually be managed by getting up slowly. Potassium supplements and/or dietary measures may be needed to control or avoid <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>.</p>
<p>Patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus should be told that furosemide may increase blood glucose levels and thereby affect urine glucose tests. The skin of some patients may be more sensitive to the effects of sunlight while taking furosemide.</p>
<p>Hypertensive patients should avoid medications that may increase blood pressure, including over-the-counter products for <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">appetite suppression</span> and <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">cold symptoms</span>.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="LINK_26a3839a-bb41-4d2f-9413-f68643075db3"></a><a name="section-8.3"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">Serum electrolytes (particularly potassium), CO<span class="Sub">2</span>, creatinine and BUN should be determined frequently during the first few months of furosemide therapy and periodically thereafter. Serum and urine electrolyte determinations are particularly important when the patient is <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> profusely or receiving parenteral fluids. Abnormalities should be corrected or the drug temporarily withdrawn. Other medications may also influence serum electrolytes.</p>
<p>Reversible elevations of BUN may occur and are associated with <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, which should be avoided, particularly in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>.</p>
<p>Urine and blood glucose should be checked periodically in diabetics receiving furosemide, even in those suspected of <span class="product-label-link" type="condition" conceptid="4311629" conceptname="Impaired glucose tolerance">latent diabetes</span>.</p>
<p>Furosemide may lower serum levels of calcium (rarely cases of <span class="product-label-link" type="condition" conceptid="380534" conceptname="Tetany">tetany</span> have been reported) and magnesium. Accordingly, serum levels of these electrolytes should be determined periodically.</p>
<p>In premature infants furosemide may precipitate <span class="product-label-link" type="condition" conceptid="4171974" conceptname="Nephrocalcinosis">nephrocalcinosis</span>/<span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">nephrolithiasis</span>, therefore renal function must be monitored and renal ultrasonography performed (see <span class="Bold"><a href="#LINK_d17a7aea-bad5-41c0-816d-31061a833bf2">PRECAUTIONS: Pediatric Use</a></span>).</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="LINK_1f918ac3-11da-49e4-8acd-e289712b74dc"></a><a name="section-8.4"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Furosemide may increase the ototoxic potential of aminoglycoside antibiotics, especially in the presence of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Except in life-threatening situations, avoid this combination.</p>
<p>Furosemide should not be used concomitantly with ethacrynic acid because of the possibility of <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">ototoxicity</span>. Patients receiving high doses of salicylates concomitantly with furosemide, as in rheumatic disease, may experience salicylate toxicity at lower doses because of competitive renal excretory sites.</p>
<p>There is a risk of ototoxic effects if cisplatin and furosemide are given concomitantly. In addition, <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> of nephrotoxic drugs such as cisplatin may be enhanced if furosemide is not given in lower doses and with positive fluid balance when used to achieve forced <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> during cisplatin treatment.</p>
<p>Furosemide has a tendency to antagonize the skeletal muscle relaxing effect of tubocurarine and may potentiate the action of succinylcholine.</p>
<p>Lithium generally should not be given with diuretics because they reduce lithium's renal clearance and add a high risk of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span>.</p>
<p>Furosemide combined with angiotensin converting enzyme inhibitors or angiotensin II receptor blockers may lead to severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and deterioration in renal function, including <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>. An interruption or reduction in the dosage of furosemide, angiotensin converting enzyme inhibitors, or angiotensin receptor blockers may be necessary.</p>
<p>Potentiation occurs with ganglionic or peripheral adrenergic blocking drugs.</p>
<p>Furosemide may decrease arterial responsiveness to norepinephrine. However, norepinephrine may still be used effectively.</p>
<p>Simultaneous administration of sucralfate and furosemide tablets may reduce the natriuretic and antihypertensive effects of furosemide. Patients receiving both drugs should be observed closely to determine if the desired diuretic and/or antihypertensive effect of furosemide is achieved. The intake of furosemide and sucralfate should be separated by at least two hours.</p>
<p>In isolated cases, intravenous administration of furosemide within 24 hours of taking chloral hydrate may lead to <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> attacks, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, increase in blood pressure, and <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>. Use of furosemide concomitantly with chloral hydrate is therefore not recommended.</p>
<p>Phenytoin interferes directly with renal action of furosemide. There is evidence that treatment with phenytoin leads to decrease intestinal absorption of furosemide, and consequently to lower peak serum furosemide concentrations.</p>
<p>Methotrexate and other drugs that, like furosemide, undergo significant renal tubular secretion may reduce the effect of furosemide. Conversely, furosemide may decrease renal elimination of other drugs that undergo tubular secretion. High-dose treatment of both furosemide and these other drugs may result in elevated serum levels of these drugs and may potentiate their toxicity as well as the toxicity of furosemide.</p>
<p>Furosemide can increase the risk of cephalosporin-induced <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> even in the setting of minor or transient <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.</p>
<p>Concomitant use of cyclosporine and furosemide is associated with increased risk of <span class="product-label-link" type="condition" conceptid="74892" conceptname="Articular gout">gouty arthritis</span> secondary to furosemide-induced hyperurecemia and cyclosporine impairment of renal urate excretion.</p>
<p>One study in six subjects demonstrated that the combination of furosemide and acetylsalicylic acid temporarily reduced creatinine clearance in patients with <span class="product-label-link" type="condition" conceptid="198185" conceptname="Chronic renal failure">chronic renal insufficiency</span>. There are case reports of patients who developed increased BUN, serum creatinine and serum potassium levels, and <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> when furosemide was used in conjunction with NSAIDs.</p>
<p>Literature reports indicate that coadministration of indomethacin may reduce the natriuretic and antihypertensive effects of furosemide in some patients by inhibiting prostaglandin synthesis. Indomethacin may also affect plasma renin levels, aldosterone excretion, and renin profile evaluation. Patients receiving both indomethacin and furosemide should be observed closely to determine if the desired diuretic and/or antihypertensive effect of furosemide is achieved.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="LINK_f7df2f33-9a68-4c2b-a4e4-d66464fa0345"></a><a name="section-8.5"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Furosemide was tested for carcinogenicity by oral administration in one <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> of mice and one <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> of rats. A small but significantly increased incidence of mammary gland carcinomas occurred in female mice at a dose 17.5 times the maximum human dose of 600 mg. There were marginal increases in uncommon tumors in male rats at a dose of 15 mg/kg (slightly greater than the maximum human dose) but not at 30 mg/kg.</p>
<p>Furosemide was devoid of mutagenic activity in various <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> typhimurium</span> when tested in the presence or absence of an <span class="Italics">in vitro</span> metabolic activation system, and questionably positive for gene mutation in mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cells in the presence of rat liver S9 at the highest dose tested. Furosemide did not induce sister chromatid exchange in human cells <span class="Italics">in vitro</span>, but other studies on chromosomal aberrations in human cells <span class="Italics">in vitro</span> gave conflicting results. In Chinese hamster cells it induced chromosomal damage but was questionably positive for sister chromatid exchange. Studies on the induction by furosemide of chromosomal aberrations in mice were inconclusive. The urine of rats treated with this drug did not induce gene conversion in <span class="Italics">Saccharomyces cerevisiae</span>.</p>
<p>Furosemide produced no impairment of fertility in male or female rats, at 100 mg/kg/day (the maximum effective diuretic dose in the rat and 8 times the maximal human dose of 600 mg/day).</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="LINK_a235a4c3-b429-44da-9581-6acb1ca1f64e"></a><a name="section-8.6"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="LINK_919d19fb-ec32-4d4e-84df-73c9a504244e"></a><a name="section-8.6.1"></a><p></p>
<h3>Pregnancy Category C</h3>
<p class="First">Furosemide has been shown to cause unexplained maternal <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> and abortions in rabbits at 2, 4 and 8 times the maximal recommended human dose. There are no adequate and well-controlled studies in pregnant women. Furosemide should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
<p>Treatment during pregnancy requires monitoring of fetal growth because of the potential for higher birth weights.</p>
<p>The effects of furosemide on embryonic and fetal development and on pregnant dams were studied in mice, rats and rabbits.</p>
<p>Furosemide caused unexplained maternal <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> and abortions in the rabbit at the lowest dose of 25 mg/kg (2 times the maximal recommended human dose of 600 mg/day). In another study, a dose of 50 mg/kg (4 times the maximal recommended human dose of 600 mg/day) also caused maternal <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> and abortions when administered to rabbits between Days 12 and 17 of gestation. In a third study, none of the pregnant rabbits survived a dose of 100 mg/kg. Data from the above studies indicate fetal lethality that can precede maternal <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>.</p>
<p>The results of the mouse study and one of the three rabbit studies also showed an increased incidence and severity of <span class="product-label-link" type="condition" conceptid="433811" conceptname="Hydronephrosis">hydronephrosis</span> (<span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span> of the renal pelvis and, in some cases, of the ureters) in fetuses derived from the treated dams as compared with the incidence in fetuses from the control group.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="LINK_2601e836-4d75-494f-bd91-6d71b9f7eca3"></a><a name="section-8.7"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Because it appears in breast milk, caution should be exercised when furosemide is administered to a nursing mother.</p>
<p>Furosemide may inhibit lactation.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="LINK_d17a7aea-bad5-41c0-816d-31061a833bf2"></a><a name="section-8.8"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">In premature infants furosemide may precipitate <span class="product-label-link" type="condition" conceptid="4171974" conceptname="Nephrocalcinosis">nephrocalcinosis</span>/<span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">nephrolithiasis</span>. <span class="product-label-link" type="condition" conceptid="4171974" conceptname="Nephrocalcinosis">Nephrocalcinosis</span>/<span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">nephrolithiasis</span> has also been observed in children under 4 years of age with no history of <span class="product-label-link" type="condition" conceptid="439128" conceptname="Extreme immaturity">prematurity</span> who have been treated chronically with furosemide. Monitor renal function, and renal ultrasonography should be considered, in pediatric patients receiving furosemide.</p>
<p>If furosemide is administered to premature infants during the first weeks of life, it may increase the risk of persistence of <span class="product-label-link" type="condition" conceptid="315922" conceptname="Patent ductus arteriosus">patent ductus arteriosus</span>.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="LINK_3b8780d6-0914-4a2f-982e-e89a38d1d1c3"></a><a name="section-8.9"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Controlled clinical studies of furosemide did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for the elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.</p>
<p>This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection and it may be useful to monitor renal function (see <span class="Bold"><a href="#LINK_96f3df82-3837-4f74-bf02-d4e46a0c9b95">PRECAUTIONS: General</a></span> and <span class="Bold"><a href="#LINK_3d2a4ff6-bc1e-465d-9cf1-6be94b98be1c">DOSAGE AND ADMINISTRATION</a></span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_f84bf29e-1fc5-4793-a4f9-0eba8192a791"></a><a name="section-9"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Adverse reactions are categorized below by organ system and listed by decreasing severity.</p>
<p><span class="Bold">Gastrointestinal System Reactions</span></p>
<ol class="Arabic">
<li><span class="product-label-link" type="condition" conceptid="4029488" conceptname="Hepatic encephalopathy">hepatic encephalopathy</span> in patients with hepatocellular insufficiency</li>
<li><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span></li>
<li><span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> (intrahepatic <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>)</li>
<li><p class="First">increased liver enzymes</p></li>
<li><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span></li>
<li>oral and <span class="product-label-link" type="condition" conceptid="4002232" conceptname="Epigastric discomfort">gastric irritation</span></li>
<li>cramping</li>
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></li>
<li><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span></li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></li>
<li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
</ol>
<p><span class="Bold">Systemic <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></span></p>
<ol class="Arabic">
<li><p class="First">Severe anaphylactic or <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> (e.g., with <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>)</p></li>
<li>systemic <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span></li>
<li>interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span></li>
<li>necrotizing <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">angiitis</span></li>
</ol>
<p><span class="Bold">Central Nervous System Reactions</span></p>
<ol class="Arabic">
<li><span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span> and <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span></li>
<li><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span></li>
<li><span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span></li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></li>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></li>
<li><span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span></li>
<li><span class="product-label-link" type="condition" conceptid="4168789" conceptname="Xanthopsia">xanthopsia</span></li>
</ol>
<p><span class="Bold">Hematologic Reactions</span></p>
<ol class="Arabic">
<li><span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span> </li>
<li><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span></li>
<li><span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> </li>
<li><span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span></li>
<li><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span></li>
<li><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span></p></li>
</ol>
<p><span class="Bold">Dermatologic-<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></span></p>
<ol class="Arabic">
<li><span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span></li>
<li><span class="product-label-link" type="condition" conceptid="139899" conceptname="Pemphigoid">bullous pemphigoid</span></li>
<li><span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span></li>
<li><span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span></li>
<li><span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span></li>
<li><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span></li>
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></li>
<li><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span></p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span></p></li>
</ol>
<p><span class="Bold">Cardiovascular Reaction</span></p>
<ol class="Arabic">
<li><span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic hypotension</span> may occur and be aggravated by alcohol, barbiturates or narcotics.</li>
<li>Increase in <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and triglyceride serum levels</li>
</ol>
<p><span class="Bold">Other Reactions</span></p>
<ol class="Arabic">
<li><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span></li>
<li><span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">glycosuria</span></li>
<li><span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span></li>
<li><span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasm</span></li>
<li><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span></li>
<li><span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span></li>
<li>urinary <span class="product-label-link" type="condition" conceptid="4090870" conceptname="Spasm of bladder">bladder spasm</span></li>
<li><span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span></li>
<li><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span></li>
</ol>
<p>Whenever adverse reactions are moderate or severe, furosemide dosage should be reduced or therapy withdrawn.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="LINK_f1d0981b-60be-48bc-a806-467f13cbb945"></a><a name="section-10"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">The principal signs and symptoms of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with furosemide are <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, blood volume reduction, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> and <span class="product-label-link" type="condition" conceptid="4289304" conceptname="Hypochloremic alkalosis">hypochloremic alkalosis</span>, and are extensions of its diuretic action.</p>
<p>The acute toxicity of furosemide has been determined in mice, rats and dogs. In all three, the oral LD<span class="Sub">50</span> exceeded 1000 mg/kg body weight, while the intravenous LD<span class="Sub">50</span> ranged from 300 to 680 mg/kg. The acute intragastric toxicity in neonatal rats is 7 to 10 times that of adult rats.</p>
<p>The concentration of furosemide in biological fluids associated with toxicity or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> is not known.</p>
<p>Treatment of overdosage is supportive and consists of replacement of excessive fluid and electrolyte losses. Serum electrolytes, <span class="product-label-link" type="condition" conceptid="4135927" conceptname="Carbon dioxide">carbon dioxide</span> level and blood pressure should be determined frequently. Adequate drainage must be assured in patients with urinary bladder outlet obstruction (such as <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span>).</p>
<p>Hemodialysis does not accelerate furosemide elimination.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_3d2a4ff6-bc1e-465d-9cf1-6be94b98be1c"></a><a name="section-11"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_3aafd0d1-9597-42c4-a423-db065cdf93f1"></a><a name="section-11.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></h2>
<p class="First">Therapy should be individualized according to patient response to gain maximal therapeutic response and to determine the minimal dose needed to maintain that response.</p>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_a80e49cf-a6c8-4f21-9ac6-7a155da0c676"></a><a name="section-11.1.1"></a><p></p>
<h3><span class="Bold">Adults:</span></h3>
<p class="First">The usual initial dose of furosemide tablets is 20 to 80 mg given as a single dose. Ordinarily a prompt <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> ensues. If needed, the same dose can be administered 6 to 8 hours later or the dose may be increased. The dose may be raised by 20 or 40 mg and given not sooner than 6 to 8 hours after the previous dose until the desired <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuretic effect</span> has been obtained. The individually determined single dose should then be given once or twice daily (e.g., at 8 am and 2 pm). The dose of furosemide tablets may be carefully titrated up to 600 mg/day in patients with clinically severe edematous states.</p>
<p><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> may be most efficiently and safely mobilized by giving furosemide tablets on 2 to 4 consecutive days each week.</p>
<p>When doses exceeding 80 mg/day are given for <span class="product-label-link" type="condition" conceptid="4088438" conceptname="Prolonged periods">prolonged periods</span>, careful clinical observation and laboratory monitoring are particularly advisable (see <span class="Bold"><a href="#LINK_26a3839a-bb41-4d2f-9413-f68643075db3">PRECAUTIONS: Laboratory Tests</a></span>).</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="LINK_d871c21f-006b-4347-9452-15518192ce2a"></a><a name="section-11.1.2"></a><p></p>
<h3><span class="Bold">Geriatric Patients:</span></h3>
<p class="First">In general, dose selection for the elderly patient should be cautious, usually starting at the low end of the dosing range (see <span class="Bold"><a href="#LINK_3b8780d6-0914-4a2f-982e-e89a38d1d1c3">PRECAUTIONS: Geriatric Use</a></span>).</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="LINK_269eaa7a-d036-425f-8634-5897f4d86da9"></a><a name="section-11.1.3"></a><p></p>
<h3><span class="Bold">Pediatric Patients:</span></h3>
<p class="First">The usual initial dose of oral furosemide tablets in pediatric patients is 2 mg/kg body weight, given as a single dose. If the diuretic response is not satisfactory after the initial dose, dosage may be increased by 1 or 2 mg/kg no sooner than 6 to 8 hours after the previous dose. Doses greater than 6 mg/kg body weight are not recommended. For maintenance therapy in pediatric patients, the dose should be adjusted to the minimum effective level.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_76eefe6f-3b3c-4972-a869-e15f97e3d52c"></a><a name="section-11.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></h2>
<p class="First">Therapy should be individualized according to the patient's response to gain maximal therapeutic response and to determine the minimal dose needed to maintain the therapeutic response.</p>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_3e6c1512-b763-4c42-9cf2-c4f11de86a58"></a><a name="section-11.2.1"></a><p></p>
<h3><span class="Bold">Adults:</span></h3>
<p class="First">The usual initial dose of furosemide tablets for <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> is 80 mg, usually divided into 40 mg twice a day. Dosage should then be adjusted according to response. If response is not satisfactory, add other antihypertensive agents.</p>
<p>Changes in blood pressure must be carefully monitored when furosemide tablets are used with other antihypertensive drugs, especially during initial therapy. To prevent excessive <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">drop in blood pressure</span>, the dosage of other agents should be reduced by at least 50 percent when furosemide tablets are added to the regimen. As the blood pressure <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span> under the potentiating effect of furosemide tablets, a further reduction in dosage or even discontinuation of other antihypertensive drugs may be necessary.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="LINK_d655895e-6c9c-493e-8168-86e7c18bace4"></a><a name="section-11.2.2"></a><p></p>
<h3><span class="Bold">Geriatric Patients:</span></h3>
<p class="First">In general, dose selection and dose adjustment for the elderly patient should be cautious, usually starting at the low end of the dosing range (see <span class="Bold"><a href="#LINK_3b8780d6-0914-4a2f-982e-e89a38d1d1c3">PRECAUTIONS: Geriatric Use</a></span>).</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_b5819cca-3122-436c-8251-defe822bfefd"></a><a name="section-12"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First"><span class="Bold">Furosemide Tablets, USP</span></p>
<p><span class="Bold">20 mg:</span> White-off white, oval, debossed "3169" on one side and debossed "V" on the reverse side, in bottles of 10, 100, 1000 and 5000.</p>
<p><span class="Bold">40 mg:</span> White-off white, round, scored, debossed "3170" over "V" on one side and plain on the reverse side, in bottles of 10, 100, 1000 and 5000.</p>
<p><span class="Bold">80 mg:</span> White-off white, round, scored, debossed "3171" over "V" on one side and plain on the reverse side, in bottles of 10, 90, 100, 180, 500 and 1000.</p>
<div class="Section" data-sectionCode="44425-7">
<a name="LINK_924997b9-2d48-42ff-adea-c69754f51a07"></a><a name="section-12.1"></a><p></p>
<h2>STORAGE</h2>
<p class="First">Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature].</p>
<p>Protect from light.</p>
<p>Dispense in well-closed, light-resistant containers. Exposure to light might cause a slight discoloration. Discolored tablets should not be dispensed.</p>
<p>Tested by USP Dissolution Test 1</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_5cb347c3-18b3-4578-848b-18e3b7d39567"></a><a name="section-13"></a><p></p>
<h1></h1>
<p class="First">Manufactured for:<br><span class="Bold">QUALITEST PHARMACEUTICALS</span><br>Huntsville, AL 35811</p>
<p>8180952<br>R6/11-R7</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_fe575b98-6ffe-411a-a344-8587edf3cdc0"></a><a name="section-14"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<div class="Figure"><img alt="55289118 Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ea5805d3-400b-4978-b27d-bd2b5b1cb636&amp;name=55289118.jpg"></div>
<br>PDRx Label<br>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>FUROSEMIDE 		
					</strong><br><span class="contentTableReg">furosemide tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:55289-118(NDC:0603-3740)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>FUROSEMIDE</strong> (FUROSEMIDE) </td>
<td class="formItem">FUROSEMIDE</td>
<td class="formItem">40 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, PREGELATINIZED CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (off-white) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">3170;V</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:55289-118-04</td>
<td class="formItem">4  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:55289-118-10</td>
<td class="formItem">10  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:55289-118-14</td>
<td class="formItem">14  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:55289-118-30</td>
<td class="formItem">30  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">5</th>
<td class="formItem">NDC:55289-118-60</td>
<td class="formItem">60  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">6</th>
<td class="formItem">NDC:55289-118-90</td>
<td class="formItem">90  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">7</th>
<td class="formItem">NDC:55289-118-01</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA076796</td>
<td class="formItem">03/26/2004</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>PD-Rx Pharmaceuticals, Inc.
							(156893695)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>PD-Rx Pharmaceuticals, Inc. (156893695)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">PD-Rx Pharmaceuticals, Inc.</td>
<td class="formItem"></td>
<td class="formItem">156893695</td>
<td class="formItem">repack</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 6/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>ced8d1ad-8432-4b85-9a36-0edabde62624</div>
<div>Set id: ea5805d3-400b-4978-b27d-bd2b5b1cb636</div>
<div>Version: 6</div>
<div>Effective Time: 20110616</div>
</div>
</div> <div class="DistributorName">PD-Rx Pharmaceuticals, Inc.</div></p>
</body></html>
